SG10201700459XA - Enhanced reconstitution and autoreconstitution of the hematopoietic compartment - Google Patents

Enhanced reconstitution and autoreconstitution of the hematopoietic compartment

Info

Publication number
SG10201700459XA
SG10201700459XA SG10201700459XA SG10201700459XA SG10201700459XA SG 10201700459X A SG10201700459X A SG 10201700459XA SG 10201700459X A SG10201700459X A SG 10201700459XA SG 10201700459X A SG10201700459X A SG 10201700459XA SG 10201700459X A SG10201700459X A SG 10201700459XA
Authority
SG
Singapore
Prior art keywords
autoreconstitution
hematopoietic compartment
enhanced reconstitution
reconstitution
enhanced
Prior art date
Application number
SG10201700459XA
Inventor
Brian C Turner
Yosef Refaeli
Gregory A Bird
Original Assignee
Taiga Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiga Biotechnologies Inc filed Critical Taiga Biotechnologies Inc
Publication of SG10201700459XA publication Critical patent/SG10201700459XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
SG10201700459XA 2012-07-20 2013-07-19 Enhanced reconstitution and autoreconstitution of the hematopoietic compartment SG10201700459XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261674224P 2012-07-20 2012-07-20
US201361785691P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
SG10201700459XA true SG10201700459XA (en) 2017-02-27

Family

ID=49949289

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201500429QA SG11201500429QA (en) 2012-07-20 2013-07-19 Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
SG10201700459XA SG10201700459XA (en) 2012-07-20 2013-07-19 Enhanced reconstitution and autoreconstitution of the hematopoietic compartment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201500429QA SG11201500429QA (en) 2012-07-20 2013-07-19 Enhanced reconstitution and autoreconstitution of the hematopoietic compartment

Country Status (12)

Country Link
US (4) US9789135B2 (en)
EP (2) EP3868387A1 (en)
JP (5) JP6285930B2 (en)
CN (3) CN110643576A (en)
AU (3) AU2013292330B2 (en)
CA (2) CA2879667C (en)
DK (1) DK2877189T3 (en)
ES (1) ES2856179T3 (en)
HK (1) HK1210719A1 (en)
IL (3) IL236763B (en)
SG (2) SG11201500429QA (en)
WO (1) WO2014015312A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
AU2009246876B2 (en) 2008-05-16 2015-04-02 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
AU2009285547B2 (en) 2008-08-28 2012-05-31 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
CA2879667C (en) * 2012-07-20 2021-11-16 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
WO2016044416A1 (en) 2014-09-16 2016-03-24 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
WO2016083777A1 (en) * 2014-11-26 2016-06-02 Isis Innovation Limited Detection of acute myeloid leukaemia (aml) leukaemic stem cells (lsc)
EP3548425B1 (en) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanoparticle formulations
EP3595683A1 (en) * 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
CA3071448A1 (en) * 2017-08-03 2019-02-07 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of cancer
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR20210149746A (en) * 2019-04-08 2021-12-09 타이가 바이오테크놀로지스, 인코포레이티드 Compositions and methods for cryopreservation of immune cells
WO2024077145A1 (en) * 2022-10-05 2024-04-11 Garuda Therapeutics, Inc. Modified hematopoietic stem cells and progenies thereof

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
JPS62501537A (en) 1984-12-21 1987-06-25 テクニクロン・リサ−チ・パ−トナ−ズ・ワン Method for electrically immortalizing lymphoid cells
DE3531430A1 (en) 1985-09-03 1987-03-05 Biotest Pharma Gmbh METHOD FOR OBTAINING COMPONENTS FROM A LIQUID WITH COMPONENTS PRESENT IN AREAS SEPARATELY SEPARATED
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4900322A (en) 1986-09-22 1990-02-13 Adams James D Blood component pooling valve and kit
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
AU781922B2 (en) 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5289858A (en) 1991-12-18 1994-03-01 Abbott Laboratories System for accommodating withdrawal of liquid from a bulk supply
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
NZ255831A (en) 1992-08-21 1997-04-24 Biogen Inc Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use
US5580760A (en) 1993-02-22 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services FUSE binding protein and cDNA therefor
WO1995003402A1 (en) 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
EP0750458B1 (en) 1994-03-03 2003-08-27 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6713247B1 (en) 1996-09-03 2004-03-30 Signal Pharmaceuticials, Inc. Human CNS cell lines and methods of use therefor
EP0975370B9 (en) 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
EP0893493A3 (en) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetically modified cells and their use for prophylaxis or treatment of diseases
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
JP2002505077A (en) 1997-12-10 2002-02-19 ワシントン大学 Antipathogen systems and methods of use
EP1070757B1 (en) 1998-04-08 2005-02-02 Shionogi & Co., Ltd. Methods for isolating osteoclast precursor cells and inducing the differentiation of the same into osteoclasts
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
US6451558B1 (en) 1998-08-03 2002-09-17 Novartis Ag Genes in the control of hematopoiesis
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
CA2364690A1 (en) 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
WO2000059540A1 (en) 1999-04-05 2000-10-12 Biocrystal Ltd. Assay kits and methods for immune complex-mediated activation involving shed antigens
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
WO2000061617A2 (en) 1999-04-12 2000-10-19 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
DE60032927T2 (en) 1999-11-10 2007-11-08 Rigel Pharmaceuticals, Inc., South San Francisco PROCESSES AND COMPOSITIONS CONTAINING RENILLA GFP
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
US20010049393A1 (en) 1999-12-07 2001-12-06 Whitehead Institute For Biomedical Research Methods for defining MYC target genes and uses thereof
EP1285577A4 (en) 2000-05-15 2007-05-09 Sonoko Habu Chimeric mouse having an immune system constructed with human cd34-positive cells and use thereof
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US20070248618A1 (en) 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
WO2002024899A2 (en) 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression
US20020155502A1 (en) 2000-10-30 2002-10-24 Horizon Biotechnologies, Inc. Affinity maturation by competitive selection
CA2427257C (en) 2000-11-01 2014-01-21 The Government Of The United States Of America Expression vectors able to elicit improved immune response and methods of using same
DE60131676T2 (en) 2000-12-01 2008-10-30 Central Institute For Experimental Animals PROCESS FOR MAKING A MOUSE SUITABLE FOR THE RECORDING, DIFFERENTIATION AND PROLIFERATION OF HETEROGENIC CELLS, THE MOUSE PRODUCED THEREOF AND THEIR USE
WO2002057436A2 (en) 2001-01-19 2002-07-25 Gendel Limited Red blood cell from a transgenic animal as vehicle for polypeptide delivery
JP3454818B1 (en) 2001-03-16 2003-10-06 直哉 小林 Liver cell proliferation method, liver cell obtained by the method, and use thereof
PL208712B1 (en) 2001-08-31 2011-05-31 Avidex Ltd Soluble t cell receptor
CN100506978C (en) 2001-09-21 2009-07-01 中国人民解放军军事医学科学院野战输血研究所 Hemapoietic stem/ancestral cell enriching method and its in vitro directional induction and differentiation
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
EP1469877A4 (en) 2001-11-02 2008-08-20 Tanox Inc B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
EP1572933A4 (en) 2002-02-13 2007-09-05 Univ Duke Modulation of immune response by non-peptide binding stress response polypeptides
CN1240439C (en) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 Genetic switch medicine for treating tumor
US7211191B2 (en) 2004-09-30 2007-05-01 Thermogenesis Corp. Blood component separation method and apparatus
WO2003089580A2 (en) 2002-04-16 2003-10-30 Dana-Farber Cancer Institute, Inc. Cancer models
GB2387599B (en) 2002-04-17 2005-08-10 Jason Peter Brown Methods for producing antibodies
CN105566497A (en) 2002-05-10 2016-05-11 新世纪药品有限公司 Ferritin fusion proteins for use in vaccines and other applications
KR101196178B1 (en) 2002-05-16 2012-11-01 버베리안 노딕 에이/에스 Fusion protein of hiv regulatory/accessory proteins
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
DK1408114T3 (en) 2002-10-11 2007-05-07 Imvision Gmbh Modular antigen transporter molecules (MAT molecules) for modulating immune responses, associated constructs, methods and applications
US20060154331A1 (en) 2002-10-15 2006-07-13 Nili Avidan Erythrocyte differentiation factor, gene encoding same, and methods of use thereof
DK1558643T3 (en) 2002-11-09 2009-09-07 Immunocore Ltd Cell receptor presentation
EP1570061A2 (en) 2002-12-05 2005-09-07 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US7482016B2 (en) 2003-03-19 2009-01-27 The J. David Gladstone Institutes Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
MXPA05012080A (en) 2003-05-08 2006-02-22 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells.
WO2005014785A2 (en) 2003-06-18 2005-02-17 The George Washington University Conditionally-immortalized hematopoietic progenitor cell lines
WO2005084158A2 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
RU2367468C2 (en) * 2003-11-19 2009-09-20 Мерк Патент Гмбх Bcl-2 PROTEINS, FRAGMENTS THEREOF, AND APPLICATION THEREOF IN PATIENTS WITH MALIGNANT TUMOUR
US7705049B2 (en) 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
CA2567349C (en) 2004-05-19 2012-11-27 Avidex Ltd Method of improving t cell receptors
EP1765860B1 (en) 2004-05-19 2008-12-10 MediGene Ltd. High affinity ny-eso t cell receptor
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
WO2006137836A2 (en) 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
GB0420963D0 (en) 2004-09-21 2004-10-20 Reneuron Ltd Hepatocyte
US7767453B2 (en) 2004-10-20 2010-08-03 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
US8795650B2 (en) 2004-12-09 2014-08-05 The Regents Of The University Of California Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells
US20060156422A1 (en) 2005-01-10 2006-07-13 Medical Research Council Methods and compositions for the generation of antibodies
WO2006104978A2 (en) 2005-03-25 2006-10-05 Curagen Corporation Antibodies against the tenascin major antigens
CA2609342A1 (en) 2005-04-26 2006-11-02 Andrei L. Gartel Nucleoside compounds and methods of use thereof
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
US20090317377A1 (en) 2005-08-26 2009-12-24 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US20070047583A1 (en) 2005-08-29 2007-03-01 Siemens Aktiengesellschaft Method for using a short address in a packet header
AU2006304392B2 (en) * 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
AU2006311725B2 (en) 2005-11-04 2011-11-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of NAV1.8 gene
EP1792627A1 (en) 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
JP2010521170A (en) 2007-03-13 2010-06-24 ナショナル ジューイッシュ ヘルス Antibody production methods
WO2009059304A2 (en) 2007-11-02 2009-05-07 Taiga Biotechnologies, Inc. Compounds for treating abnormal cellular proliferation
RU2010139426A (en) 2008-03-17 2012-04-27 Зе Скрипс Ресеч Инститьют (Us) COMBINATION OF CHEMICAL AND GENETIC APPROACHES TO OBTAINING INDUCED PLURIPOTENT STEM CELLS
AU2009246876B2 (en) 2008-05-16 2015-04-02 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
WO2009149956A2 (en) 2008-06-13 2009-12-17 Life & Brain Gmbh Fusion protein and use thereof
DK2313496T3 (en) 2008-07-21 2014-12-15 Taiga Biotechnologies Inc Anukleære differentiated cells, and method for preparation thereof
AU2009285547B2 (en) 2008-08-28 2012-05-31 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
AU2009313290B2 (en) * 2008-11-06 2016-04-21 Indiana University Research & Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
CN102272153B (en) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 High affinity t cell receptor and use thereof
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US20120107317A1 (en) 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2689512T3 (en) 2011-09-15 2018-11-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors that recognize MAGE restricted by HLA-A1 or HLA-Cw7
WO2013042125A2 (en) 2011-09-21 2013-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nano delivery systems
CA2872471C (en) 2012-05-03 2022-11-22 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
WO2013177419A2 (en) 2012-05-23 2013-11-28 The Ohio State University Lipid nanoparticle compositions and methods of making and methods of using the same
DE102012209673A1 (en) 2012-06-08 2013-12-24 Artcline Gmbh A method for producing a leukocyte preparation and leukocyte preparation
CA2879667C (en) * 2012-07-20 2021-11-16 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
WO2014018863A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
US20140109246A1 (en) 2012-09-24 2014-04-17 The Regents Of The University Of Colorado, A Body Corporate Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN105163744A (en) 2013-03-01 2015-12-16 美国卫生和人力服务部 Methods of producing enriched populations of tumor-reactive T cells from tumor
US9844569B2 (en) 2013-03-01 2017-12-19 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
KR20160145186A (en) 2014-04-24 2016-12-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Application of induced pluripotent stem cells to generate adoptive cell therapy products
JP6743022B2 (en) 2014-12-24 2020-08-19 ネクシミューン インコーポレイテッド Nanoparticle compositions and methods for immunotherapy
KR20180081507A (en) 2015-10-02 2018-07-16 다나-파버 캔서 인스티튜트 인크. Combination therapy of bromo-domain inhibitor and blocking
US10712344B2 (en) 2016-01-15 2020-07-14 Berkeley Lights, Inc. Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
WO2018104909A2 (en) 2016-12-09 2018-06-14 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Also Published As

Publication number Publication date
US9789135B2 (en) 2017-10-17
AU2018247295A1 (en) 2018-11-01
JP2019178180A (en) 2019-10-17
DK2877189T3 (en) 2021-02-22
ES2856179T3 (en) 2021-09-27
AU2013292330A1 (en) 2015-03-12
HK1210719A1 (en) 2016-05-06
JP2022145801A (en) 2022-10-04
AU2020267206A1 (en) 2020-12-10
IL272532A (en) 2020-03-31
JP6285930B2 (en) 2018-02-28
US20180117089A1 (en) 2018-05-03
AU2020267206B2 (en) 2024-05-16
AU2018247295B2 (en) 2020-11-26
US20150164950A1 (en) 2015-06-18
SG11201500429QA (en) 2015-03-30
US10206952B2 (en) 2019-02-19
JP2018095654A (en) 2018-06-21
EP2877189B1 (en) 2021-01-06
IL284998A (en) 2021-08-31
US20210177907A1 (en) 2021-06-17
JP2015524415A (en) 2015-08-24
CA2879667C (en) 2021-11-16
IL236763B (en) 2020-02-27
CA2879667A1 (en) 2014-01-23
EP3868387A1 (en) 2021-08-25
EP2877189A1 (en) 2015-06-03
EP2877189A4 (en) 2016-11-09
JP6851435B2 (en) 2021-03-31
JP2021088608A (en) 2021-06-10
CN114645015A (en) 2022-06-21
JP6564892B2 (en) 2019-08-21
US20190142870A1 (en) 2019-05-16
CN110643576A (en) 2020-01-03
CA3133302A1 (en) 2014-01-23
IL272532B (en) 2021-08-31
JP7122424B2 (en) 2022-08-19
AU2013292330B2 (en) 2018-07-12
WO2014015312A1 (en) 2014-01-23
IL236763A0 (en) 2015-03-31
CN104640551A (en) 2015-05-20
US10953048B2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
IL284998A (en) Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
GB2510665B (en) Absorbent articles with channels and signals
EP2870505A4 (en) Anti-glare and anti-sparkle transparent structures
SG11201404422WA (en) Polyolefin adhesive compositions and methods of preparing the same
HK1211274A1 (en) Sealing arrangement and container associated with same
HUE042637T2 (en) Laminates and methods of making the same
IL230650A (en) Methylphenidate-prodrugs and processes of making and using the same
HK1210949A1 (en) Combinations and uses thereof
GB2505055B (en) Transparent shell structure for luggage and the like
EP2923054A4 (en) Composite articles and methods
HK1207847A1 (en) Slide and shell container with ledge
EP2901512A4 (en) Sealing member and battery comprising the same
EP2938415A4 (en) Materials and methods
EP2909285A4 (en) Gelling agents and methods of using the same
SG10201701154RA (en) Anti-viral methods and the use of an anti-viral agent
IL235426A0 (en) Nucleic acid construct and use of the same
EP2920312A4 (en) Oncolytic hsv1 vectors and methods of using the same
EP2758530A4 (en) Shigella-derived vector and methods of using the same
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-
EP2924046A4 (en) Novel complex and use of same
PL2830587T3 (en) Dermo-protective and dermo-balancing composition
GB201222541D0 (en) Kiddibidet and pottibidet
HK1186341A2 (en) Fertilizer in the form of toothpaste
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder